Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/26/2025

Janusmed sex and gender

Janusmed sex and gender – Saknas

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Zuclopenthixol testing environment

Zuclopenthixol

Class : B

Show all info

Print

Contact us

  1. Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400.

  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]

  1. Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400.
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-08-19.]
A A
A A

Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) testing environment

Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)

Class : A

Show all info

Print

Contact us

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.

  4. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Gardasil 9 (human papillomavirus vaccine, types 6, 11, 16, 18, 31,33, 45, 52, 58). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
  4. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
A A
A A

Vaccine for human papillomavirus (types 6, 11, 16, 18) testing environment

Vaccine for human papillomavirus (types 6, 11, 16, 18)

Class : A

Show all info

Print

Contact us

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.

  4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.

  5. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.

  6. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.

  7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.

  8. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.

  9. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.
  4. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
  5. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.
  6. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.
  7. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
  8. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.
  9. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
A A
A A

Vaccine for human papillomavirus (types 16 and 18) testing environment

Vaccine for human papillomavirus (types 16 and 18)

Class : A

Show all info

Print

Contact us

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.

  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.

  3. Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.

  4. Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].

  5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.

  6. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.

  7. Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.

  8. Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.

  9. Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.

  10. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017

  1. Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
  2. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
  3. Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
  4. Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].
  5. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.
  6. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.
  7. Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
  8. Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.
  9. Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.
  10. Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
A A
A A

Podophyllotoxin testing environment

Podophyllotoxin

Class : A

Show all info

Print

Contact us

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.

  2. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 05% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194-9.

  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
  2. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 05% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194-9.
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]